Flint emc7/31/2023 ![]() As always, our research needs to be directed at solving clinically-relevant issues that promote patient safety and patient outcome.įor the publications concerning our research line Medication Optimization and Safety, click here.įor the publications concerning our research line Clinical Pharmacometrics, click here.įor the publications concerning our research line Drug Innovation, click here. The Department of Pharmacy is committed to increasing the quantity and quality of our scientific output, and we aim for the first quartile of MNCS scores within the Erasmus MC.The Department of Radiology and Nuclear Medicine is seeking cooperation with our department in this area, but successful further development of this research line will take another three to five years. The Erasmus MC has a track record in this field with the development of Lutetium for NET cancer. Radiopharmacy is also fast becoming a new research opportunity. The second line might cooperate with the Department of Haematology to focus on the use – and our own production of – T-cells. The first line will focus on oncolytic viruses in cooperation with the Department of Virology. This research line is still in development, but it might lead to two separate lines in the future. Several groups within the Erasmus MC perform cutting-edge clinical research with ATMPs, which offers the potential for the strong involvement of a dedicated ATMP pharmacist. ![]() The involvement of a pharmacist is crucial here, in terms of advice and oversight regarding preparation, handling and storage activities for ATMPs. The Erasmus MC will build a new ATMP facility.We will focus on several developments that can influence and increase our research possibilities: Research line 2: Clinical Pharmacometrics. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |